Spain's leading drugmaker Almirall (ALM: MC) has reported that its total revenue in the first half of 2016 was 428.1 million euros ($470.8 million), which is 5% higher than in the same period of 2015.
The announcement of the latest financial results on Tuesday sent Almirall’s share price soaring by 8% to 14.46 euros in afternoon trading.
Growth was driven by dermatology, sales in which have risen 13.3% since last year, and this therapy area now accounts for 43% of the company’s sales, compared to 41% in the first half of 2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze